(855) 575-6376

Mesothelioma Statistics [Updated 2026]: Incidence, Survival & Legal Data

Legally Reviewed by Joseph P. Williams on June 9, 2026

Mesothelioma is a rare cancer caused almost exclusively by asbestos exposure. Understanding its statistics — how common it is, who it affects, how it is treated, and how it compares across states — helps patients and families contextualize their diagnosis and understand the medical and legal landscape they are navigating. The data below reflect the most current available information from the CDC, the National Cancer Institute, and peer-reviewed literature.

At The Williams Law Firm, P.C., Attorney Joseph P. Williams has been representing mesothelioma victims for more than 30 years. He has never lost a mesothelioma case. If you or a loved one has been diagnosed with mesothelioma, contact our firm through our contact form for a free consultation.

⚠ Time-Sensitive — New York Law Limits Your Window to File

Diagnosed with mesothelioma? New York’s 3-year statute of limitations runs from your diagnosis date, not your exposure date.

Over 1,000 families represented. Hundreds of millions recovered. Never lost a mesothelioma case. No fees unless we win.

Get a Free Case Review
✆ (855) 575-6376

Key U.S. Mesothelioma Statistics

  • Approximately 3,000 new mesothelioma cases are diagnosed in the United States each year.
  • Mesothelioma accounts for approximately 0.3 percent of all cancer diagnoses, making it rare but disproportionately deadly.
  • From 1999 to 2020, the age-adjusted incidence rate of mesothelioma in the U.S. declined by approximately 27 percent as a direct result of reduced asbestos use.
  • Despite the decline in incidence, mesothelioma deaths have remained relatively stable because the latency period of 20 to 50 years means current diagnoses reflect asbestos exposures from the 1960s through the 1990s.
  • Asbestos-related diseases including mesothelioma, asbestos-related lung cancer, and asbestosis are estimated to account for 12,000 to 15,000 deaths in the United States each year.
  • Men are 4.6 times more likely to be diagnosed with mesothelioma than women, reflecting occupational exposure patterns.
  • The average age at mesothelioma diagnosis is 74 for men and 72 for women.
  • Mesothelioma death rates are highest in the Northeast, Midwest, and Northwest, reflecting the industrial history of those regions.

U.S. Cancer Statistics in Context

  • From 2001 to 2020, overall cancer death rates in the U.S. decreased by 27 percent.
  • Cancer is the second leading cause of death in the United States, following heart disease.
  • Lung cancer remains the leading cancer killer, accounting for more than 125,000 deaths annually — and asbestos exposure is a significant contributing cause of lung cancer independent of mesothelioma.
  • The National Cancer Institute estimates the first-year cost of lung cancer treatment at $60,000 or more — mesothelioma treatment costs are comparable and can be substantially higher depending on the treatment approach.

Mesothelioma Types — Prevalence

  • Pleural mesothelioma (lining of the lungs) accounts for 80 to 90 percent of all cases and is the most common form.
  • Peritoneal mesothelioma (lining of the abdomen) accounts for 10 to 15 percent of cases.
  • Pericardial mesothelioma (lining of the heart) accounts for less than 1 percent of cases.
  • Testicular mesothelioma (lining of the testes) accounts for less than 1 percent of cases.

Mesothelioma Cell Types — Prevalence

  • Epithelioid cell type accounts for approximately 70 percent of cases and has the most favorable prognosis.
  • Biphasic cell type (both epithelioid and sarcomatoid) accounts for approximately 20 percent of cases.
  • Sarcomatoid cell type accounts for approximately 10 percent of cases and has the least favorable prognosis.

Mesothelioma Survival Rates

Survival rates for mesothelioma vary significantly by stage, cell type, and treatment approach. The following figures reflect median survival for pleural mesothelioma by stage, based on the most recent available data:

  • Stage 1: 22.2 months median survival
  • Stage 2: 20 months median survival
  • Stage 3: 17.9 months median survival
  • Stage 4: 14.9 months median survival

The overall five-year survival rate for pleural mesothelioma is approximately 12 percent. Peritoneal mesothelioma patients who qualify for cytoreductive surgery with HIPEC achieve five-year survival rates above 50 percent in some series. Patients treated at dedicated mesothelioma specialist centers with multimodal therapy consistently achieve better outcomes than the median.

Mesothelioma Treatment Statistics

  • Chemotherapy with pemetrexed and cisplatin is the most common first-line treatment, received by approximately 80 percent of mesothelioma patients.
  • Surgical treatment (pleurectomy/decortication or EPP) is appropriate for fewer than 20 percent of pleural mesothelioma patients, largely due to late-stage diagnosis.
  • The FDA approved nivolumab plus ipilimumab for unresectable pleural mesothelioma in 2020, with the CheckMate 743 trial showing median survival of 18.1 months for immunotherapy vs 14.1 months for chemotherapy.
  • Peritoneal mesothelioma patients who receive CRS/HIPEC have a 5-year survival rate exceeding 50 percent in qualified patients at experienced centers.

Latency Period Statistics

  • Mesothelioma has one of the longest latency periods of any occupational cancer, typically 20 to 50 years between first asbestos exposure and symptom onset.
  • The average latency period for men is 30 to 40 years; for women it is 50 or more years.
  • The long latency period means most patients diagnosed today were exposed during the 1960s through 1990s, when asbestos use in construction, manufacturing, and shipbuilding was at its height.

New York Mesothelioma Statistics

New York is one of the highest-exposure states in the country due to its history of shipbuilding, construction, manufacturing, and power generation industries. In a recent reporting year, approximately 160 new mesothelioma cases were diagnosed in New York State. Of those cases, approximately 110 were male and 50 female, consistent with the national gender ratio. The New York metropolitan area, including the five boroughs and the surrounding region, accounts for a disproportionate share of New York State cases due to the concentration of asbestos exposure sites in the region’s industrial and construction history.

Mesothelioma Lawsuit Statistics

  • Approximately 1,800 to 2,100 mesothelioma lawsuits are filed annually in the United States.
  • The average mesothelioma settlement value is approximately $1 to $1.4 million.
  • The average mesothelioma trial award is approximately $2.4 million.
  • In 2019, the average dollar amount per company’s resolved asbestos claims increased by 25 percent from the prior year.
  • Over 60 asbestos bankruptcy trust funds have been established with a combined total exceeding $30 billion to compensate current and future victims.

Contact The Williams Law Firm, P.C.

If you or a loved one has been diagnosed with mesothelioma, understanding your legal rights is as important as understanding your medical options. The Williams Law Firm, P.C. has recovered hundreds of millions of dollars for mesothelioma victims and their families. Attorney Joseph P. Williams has never lost a mesothelioma case. Reach out through our contact form or call our New York mesothelioma attorney team for a free consultation. You pay nothing unless we win.

Frequently Asked Questions About Mesothelioma Statistics

How many people are diagnosed with mesothelioma each year in the U.S.?

Approximately 3,000 new mesothelioma cases are diagnosed in the United States each year, according to the most recent available data from the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute. This represents a meaningful decline from peak rates in the late 1990s and early 2000s, driven by reduced asbestos exposure following regulatory restrictions beginning in the 1970s. However, because the latency period is 20 to 50 years, diagnoses will continue occurring for decades as workers exposed during the peak asbestos era develop disease.

What is the survival rate for mesothelioma?

The overall five-year survival rate for pleural mesothelioma is approximately 12 percent. Survival varies significantly by stage, cell type, and treatment approach. Stage 1 patients have median survival of approximately 22 months; stage 4 patients have median survival of approximately 15 months. Peritoneal mesothelioma patients who qualify for CRS/HIPEC at specialized centers achieve five-year survival rates above 50 percent in some series. Patients treated with multimodal therapy at dedicated mesothelioma centers consistently achieve better outcomes than the general statistics suggest.

Is mesothelioma becoming more or less common?

Mesothelioma incidence in the United States has been declining since the late 1990s, driven by the significant reduction in occupational asbestos exposure following federal regulation in the 1970s. From 1999 to 2020, the age-adjusted incidence rate dropped approximately 27 percent. However, the rate of decline has plateaued, and global mesothelioma rates remain elevated in countries that continue using asbestos. In the U.S., ongoing cases reflect exposures from decades past, and given the long latency period, new diagnoses will continue for years to come.

What is the average mesothelioma lawsuit settlement?

The average mesothelioma settlement is approximately $1 to $1.4 million, while the average trial verdict is approximately $2.4 million. Individual case values vary significantly based on the severity of illness, the patient’s age and earning history, the number of potentially liable defendants, the quality of the exposure documentation, and the jurisdiction where the case is filed. Many cases resolve through settlements with multiple defendants simultaneously. Asbestos trust fund claims provide additional compensation independent of direct litigation, and many patients receive compensation from multiple sources.

How long does mesothelioma take to develop after asbestos exposure?

Mesothelioma has a latency period of 20 to 50 years — the period between first asbestos exposure and the onset of symptoms or diagnosis. The average latency period is 35 to 40 years overall, approximately 30 to 40 years in men and 50 or more years in women. This extremely long latency period means that someone diagnosed with mesothelioma today was most likely exposed to asbestos during the 1960s, 1970s, or 1980s. The latency period does not affect the validity of a legal claim — the statute of limitations runs from the date of diagnosis, not from the date of exposure.

Joseph P. Williams

Legally Reviewed by

Joseph P. Williams
Renowned Mesothelioma Attorney

June 9, 2026

As the founding partner of Williams Law Firm, Joseph P. Williams has dedicated over 30 years to representing mesothelioma victims and their families. His firm has recovered hundreds of millions of dollars for those affected by asbestos exposure, offering personalized, aggressive legal advocacy. Based in New York, Williams Law Firm provides free consultations and handles cases nationwide.

Free consultation

  • This field is for validation purposes and should be left unchanged.
CALL TODAY